Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars

Alteogen and Sandoz sign exclusive licence agreement

Jan 2, 2023

Alteogen announced that it has entered into an exclusive licence agreement with Sandoz for the use of ALT-B4 (novel hyaluronidase derived using Alteogen’s Hybrozyme™ technology) to develop a subcutaneous version of an undisclosed Sandoz biosimilar product.  The agreement also includes an option for Sandoz to licence the Hybrozyme technology for two further products.  Alteogen will receive an upfront payment and is eligible to receive milestone payments and tiered royalties on sales of the commercialised products.  Alteogen will be responsible for the regulatory development and commercial supply of ALT-B4 to Sandoz.

Print Page Mail Article